Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07335289 · ClinicalTrials.gov registry record · NA

PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence

A NA study, sponsored by Massachusetts General Hospital.

Not yet
Registry status
NA
Development phase
400
Enrollment target

NCT07335289: Clinical Trial NA study, sponsored by Massachusetts General Hospital.

NCT07335289 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07335289, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.

NOT YET RECRUITING
Registry status
NA
Development phase
400 participants
Enrollment target

Study Summary

PrEP4U is designed as a pragmatic, randomized implementation trial to test strategies that could directly inform real-world roll-out of lenacapavir. By integrating: * Same-day initiation based on rapid HIV testing, and * Choice of follow-up delivery location (home, community, or clinic) the study addresses two of the most pressing implementation questions for long-acting injectable PrEP. The primary hypothesis is that giving participants choice in follow-up location will improve PrEP persistence compared to a clinic-only model. Secondary analyses will evaluate safety of rapid testing, acceptability, and participant costs. Exploratory analyses will assess HIV incidence and resistance. Findings from PrEP4U will provide essential evidence to guide scalable, equitable, person-centered delivery models for lenacapavir PrEP in the U.S. and globally.

Interventions

  • OTHER Choice of follow up
  • OTHER Follow up via standard clinic

Trial Details

FieldValue
Enrollment Target 400 participants
Start Date 2026-06-30
Est. Completion 2027-02-01
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT07335289

The ClinicalTrials.gov registry entry for NCT07335289 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Choice of follow up is the first listed.

NCT07335289 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07335289 about?

NCT07335289 is a clinical study titled "PrEP4U: Assessing the Effectiveness of Integrated Same-Day Lenacapavir Initiation and Follow-up Choice on PrEP Persistence". PrEP4U is designed as a pragmatic, randomized implementation trial to test strategies that could directly inform real-world roll-out of lenacapavir. By integrating: * Same-day initiation based on rapid HIV testing, and * Choice of follow-up delivery location (home, community, or clinic) the study a...

What is the current status of trial NCT07335289?

This trial is currently not yet recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2026-06-30. Estimated completion is 2027-02-01.

What interventions are being tested in trial NCT07335289?

The interventions under investigation include: Choice of follow up (OTHER), Follow up via standard clinic (OTHER).

Who is sponsoring clinical trial NCT07335289?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.